Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Myasthenia Gravis 4Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Demyelinating Diseases 1Adrenal Insufficiency 1

Interventions

eculizumab 3fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1ravulizumab 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Cytarabine 1Carmustine 1Antilymphocyte Serum 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuromyelitis Optica × ravulizumab × Clear all
NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡